|
Real-time
Euronext Paris
03:33:20 28/08/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 0.3800 EUR | -2.44% |
|
-0.65% | +27.52% |
| 27/08 | The FDA will issue its decision on Nicox's NCX 470 by the end of next April |  |
| 27/08 | US FDA to Complete Nicox's Glaucoma Drug Review by April 2027 | MT |
| Market Cap | 3.43Cr 4Cr 3.21Cr 2.94Cr 5.54Cr 381.93Cr 5.56Cr 38Cr 15Cr 192.49Cr 15Cr 15Cr 637.06Cr | P/E 2026 * |
-5.56x | P/E 2027 * | 39x |
|---|---|---|---|---|---|
| Enterprise Value | 3.43Cr 4Cr 3.21Cr 2.94Cr 5.54Cr 381.93Cr 5.56Cr 38Cr 15Cr 192.49Cr 15Cr 15Cr 637.06Cr | EV / Sales 2026 * |
11.4x | EV / Sales 2027 * | 3.43x |
| Free-Float |
99.65% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -2.44% | ||
| 1 week | -0.65% | ||
| Current month | -1.68% | ||
| 1 month | +0.80% | ||
| 3 months | -1.43% | ||
| 6 months | -20.75% | ||
| Current year | +27.52% |
| 1 week | 0.38 |  | 0.4 |
| 1 month | 0.37 | | 0.4 |
| Current year | 0.29 | | 0.57 |
| 1 year | 0.28 | | 0.57 |
| 3 years | 0.14 | | 0.65 |
| 5 years | 0.14 | | 3.84 |
| 10 years | 0.14 | | 13.68 |
| Manager | Title | Age | Since |
|---|---|---|---|
Gavin Spencer
CEO | Chief Executive Officer | 55 | 28/02/2024 |
Sandrine Gestin
DFI | Director of Finance/CFO | 58 | 01/01/2015 |
Doug Hubatsch
CTO | Chief Tech/Sci/R&D Officer | - | 13/12/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Gavin Spencer
BRD | Director/Board Member | 55 | 08/04/2024 |
Damian Marron
CHM | Chairman | 64 | 16/07/2024 |
Marc Bozec
BRD | Director/Board Member | - | 16/07/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 29/01/22 | Free | Chief Executive Officer | 15,000 | 0.0348% | ||
| 16/02/21 | Fiscal year | Chief Executive Officer | 10,000 | 0.0270% | ||
| 01/02/20 | Free | Chief Executive Officer | 10,000 | 0.0300% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.44% | -0.65% | +2.56% | -11.63% | 4Cr | |
| -2.33% | +0.37% | +77.88% | +35.69% | 37TCr | |
| -0.02% | +1.56% | +30.26% | -13.57% | 7.1TCr | |
| -0.13% | +0.75% | +46.11% | +150.46% | 1.21TCr | |
| +1.74% | +2.86% | +3.80% | +1.10% | 860.44Cr | |
| -2.31% | -0.94% | -16.02% | -0.35% | 498.8Cr | |
| -1.19% | +4.65% | -28.68% | +15.69% | 446.46Cr | |
| +1.34% | -11.74% | -32.42% | +8.76% | 322.19Cr | |
| -1.54% | -6.87% | -1.95% | +40.78% | 256.86Cr | |
| +2.75% | -4.05% | -15.05% | -3.95% | 219.51Cr | |
| Average | -0.41% | -0.44% | +6.65% | +22.30% | 4.78TCr | |
| Weighted average by Cap. | -1.79% | +0.48% | +65.09% | +29.76% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 30L 34.95L 28.09L 25.72L 48.45L 33Cr 48.59L 3.33Cr 1.3Cr 17Cr 1.31Cr 1.28Cr 56Cr | 1Cr 1.16Cr 93.62L 85.73L 1.61Cr 111.26Cr 1.62Cr 11Cr 4.33Cr 56Cr 4.37Cr 4.28Cr 185.59Cr |
| Net income | -60L -69.9L -56.17L -51.44L -96.9L -67Cr -97.17L -6.65Cr -2.6Cr -34Cr -2.62Cr -2.57Cr -111.35Cr | 10L 11.65L 9L 9L 16.15L 11Cr 16.2L 1.11Cr 43.34L 5.61Cr 43.74L 42.79L 19Cr |
| Net Debt | - | - |
Employees
10
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 28/26/28 | €0.3800 | -2.44% | 1,76,160 |
| 27/26/27 | €0.3895 | +2.64% | 4,14,664 |
| 26/26/26 | €0.3795 | -0.26% | 97,776 |
| 25/26/25 | €0.3805 | -0.52% | 1,69,554 |
| 24/26/24 | €0.3825 | 0.00% | 83,441 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.3895EUR
Average target price
1.000EUR
Spread / Average Target
+156.74%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ALCOX Stock
Select your edition
All financial news and data tailored to specific country editions
